NanoVibronix
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 16
- Market Cap
- -
- Introduction
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Elmsford, NY.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage
- Conditions
- Intubation, Nasogastric
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Nanovibronix
- Target Recruit Count
- 24
- Registration Number
- NCT00781248
- Locations
- 🇮🇱
"Bikur Cholim" Hospital, Jerusalem, Israel
The Use of the UroShield Device in Patients With Indwelling Urinary Catheters
- Conditions
- Urinary Tract Infection
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Nanovibronix
- Target Recruit Count
- 200
- Registration Number
- NCT00446732
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
News
NanoVibronix's UroShield Completes Pilot Phase for UTI Prevention
NanoVibronix has successfully completed the pilot phase of a randomized controlled trial for UroShield, a device designed to prevent catheter-associated urinary tract infections (UTIs).